Financiado en parte por Blue Regale Medical Technology Co.,Ltd, Suzhou, China
Exploring a tolerable and effective dosage of omega-3 fatty acids as a supplement in enterally fed patients with severe pneumonia: A pilot study
You Q, Chen Y, Yu H, Zhang Y, Tang N, Rao Z
Asia Pacific journal of clinical nutrition · 0 citas
Etiquetas de revisión
Financiado por la industriaDatos neutrales que nuestra revisión registró sobre cómo se hizo este estudio. Describen el método, nunca si nos gusta el resultado.
Cómo se estudió
- Diseño
- Ensayo controlado aleatorizado (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Marcadores de salud y funcionamiento
Quién lo pagó
- Financiación
- Financiado por la industria
- Empresa
- Blue Regale Medical Technology Co.,Ltd, Suzhou, China
Según 1 financiador declarado.
Publicación
- Publicado
- 2026-06-01 · Asia Pac J Clin Nutr · vol. 35 · número 3 · págs. 475–484
- Editorial
- National Institutes of Health
- Citado
- 0 citas · más que el 36% de estudios similares · 0.0× el promedio de su campo
- Referencias
- 0 trabajos
- Acceso
- Acceso abierto (copia en repositorio)
- Áreas de investigación
- Clinical Nutrition and Gastroenterology · Fatty Acid Research and Health · Respiratory Support and Mechanisms
- Palabras clave
- omega-3 fatty acids, EPA, docosahexaenoic acid, severe community-acquired pneumonia, enteral nutrition, mechanical ventilation duration, hospital costs, tolerability, immune enhancement, anti-inflammatory activity
- MeSH
- humans, fatty acids, omega-3, enteral nutrition, pilot projects, dietary supplements, aged, middle aged, female, male, community-acquired pneumonia
6 autores
- Qian You🇨🇳Sichuan University; West China Hospital of Sichuan University
- Yingyi Chen🇨🇳Sichuan University; West China Hospital of Sichuan University
- He Yu🇨🇳Sichuan University; West China Hospital of Sichuan University
- Yulian Zhang🇨🇳Sichuan Center for Disease Control and Prevention
- Na Tang🇨🇳Sichuan University; West China Hospital of Sichuan University
- Zhiyong Rao🇨🇳Sichuan University; West China Hospital of Sichuan University
Resumen
El texto original del estudio, en el idioma en que se publicó.
Background and objectives
Severe community-acquired pneumonia (CAP) is one of the most common di-agnoses in the medical intensive care unit. The objective of this study is to seek an effective and clinically tolerable dosage of ω-3 (EPA+DHA) fatty acids (FA) in enterally fed patients with severe pneumonia.
Methods and study design
A total of 84 patients were randomly assigned to a control group or two experimental groups from January 2022 to June 2024, each receiving 3.50g and 8.75g of ω-3 FA daily for 7 days, and clinical outcomes and tolerance parameters were collected.
Results
ω-3 FA supplementation significantly reduced mechanical ventilation (MV) duration, hospital expenses, and daily hospital costs. Mechanistically, the anticipated anti-inflammatory effect was not observed but a trend of immune enhancement was noted. The addition of 3.50g and 8.75g of ω-3 FA daily was relatively well-tolerated in patients with severe pneumonia.
Conclusions
In this pilot study, ω-3 FA supplementation at 3.50-8.75 g/day to enterally fed patients with severe pneumonia for 7 days was relatively well-tolerated, shortened days of MV, and decreased hospital cost. Further investigation with adequate statistical power and larger sample size is warranted to confirm these clin-ical benefits and establish the optimal dosage for this supplementation strategy.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial.
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.